|
Federal
Register Notices > Notice
of Application >
Applied Science Labs
FR Doc E7-14266 [Federal Register: July 24, 2007 (Volume 72, Number 141)] [
Notices] [Page 40331-40332] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24jy07-116]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to 1301.33(a) of Title 21 of the Code of Federal Regulations
(CFR),
this is notice that on April 24, 2007, Applied Science Labs, Division of Alltech
Associates Inc., 2701 Carolean Industrial Drive, State College, Pennsylvania
16801, made application by renewal to the Drug Enforcement Administration (DEA)
to be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedule I and II:
|
Drug
|
Schedule
|
|
Methcathinone (1237)
|
I
|
|
N-Ethylamphetamine (1475)
|
I
|
|
N,N-Dimethylamphetamine (1480)
|
I
|
|
4-Methylaminorex (cis isomer) (1590)
|
I
|
|
Alpha-ethyltryptamine (7249)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
2, 5-Dimethoxy-4-n-propylthiophenethylamine (2C-T-7) (7348)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
2-5-Dimethoxy-4-ethylamphetamine (7399)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)
|
I
|
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (7405)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Alpha-methyltryptamine (AMT) (7432)
|
I
|
|
Bufotenine (7433)
|
I
|
|
Diethyltryptamine (7434)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
5-methoxy-N-,N-diisopropyltryptamine(5-MeO-DIPT) (7439)
|
I
|
|
N-Ethyl-1-phenylcyclohexylamine (7455)
|
I
|
|
1-(1-Phenylcyclohexyl)pyrrolidine (PCPy)(7458)
|
I
|
|
1[1-(2 Thienyl)cyclohexyl]piperidine (7470)
|
I
|
|
Dihydromorphine (9145)
|
I
|
|
Normorphine (9313)
|
I
|
|
Methamphetamine (1105)
|
II
|
|
1-Phenylcylohexylamine (7460)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
Phenylacetone (8501)
|
II
|
|
1-Piperidinocyclohexanecarbonitrile (8603)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Benzoylecgonine (9180)
|
II
|
|
Meperidine intermediate-B (9233)
|
II
|
|
Noroxymorphone (9668)
|
II
|
The company plans to manufacture high purity drug standards used for
analytical application only in clinical, toxicological, and forensic
laboratories.
Any other such applicant and any person who is presently registered with DEA
to manufacture such a substance may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), Washington, DC 20537,
or any being sent via express mail should be sent to Drug Enforcement
Administration, Office of Diversion Control, Federal Register Representative (ODL),
2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no
later than September 24, 2007.
Dated: July 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E7-14266 Filed 7-23-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|
